Want to see IN:PGHL full AI Analyst Report?
Top Page
Procter & Gamble Health Ltd.
(PGHL)
Select Model
Select Model
Rating:74Outperform
Price Target:
₹7,744.00
▲(34.64% Upside)
Action:Reiterated
Date:05/28/26
Score is driven primarily by strong financial performance (high profitability, very low leverage, and improving free cash flow). This is tempered by stretched technical conditions (overbought signals despite an uptrend) and a relatively high valuation multiple, partly offset by the dividend yield.
Positive Factors
Conservative Balance Sheet
Very low leverage and ample equity backing reduce financial risk and preserve strategic optionality. A conservative capital structure supports sustained investment in distribution and brand-building, makes the company resilient to demand swings, and lowers refinancing pressure over months.
Negative Factors
Revenue Volatility / 2024 Dip
A prior revenue decline signals vulnerability in demand or channel execution; inconsistent top-line growth complicates multi-quarter planning for marketing and distribution scale. If not addressed, revenue volatility can slow sustainable market-share gains in a competitive OTC space.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative Balance Sheet
Very low leverage and ample equity backing reduce financial risk and preserve strategic optionality. A conservative capital structure supports sustained investment in distribution and brand-building, makes the company resilient to demand swings, and lowers refinancing pressure over months.
Read all positive factors
Procter & Gamble Health Ltd. (PGHL) vs. iShares MSCI India ETF (INDA)
Market Cap
₹112.84B
Dividend Yield3.28%
Average Volume (3M)310.00
Price to Earnings (P/E)34.5
Beta (1Y)0.49
Revenue Growth13.04%
EPS Growth4.60%
CountryIN
Employees1,336
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)184.83
Shares Outstanding16,599,382
10 Day Avg. Volume340
30 Day Avg. Volume310
Financial Highlights & Ratios
PEG Ratio0.81
Price to Book (P/B)15.22
Price to Sales (P/S)5.67
P/FCF Ratio24.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)215.9
Revenue Forecast (FY)₹15.00B
Procter & Gamble Health Ltd. Business Overview & Revenue Model
Company Description
Procter & Gamble Health Limited is an Indian entity focused on the production and distribution of pharmaceutical products and chemicals. Its extensive product portfolio includes a variety of over-the-counter (OTC) medications, as well as vitamins,...
How the Company Makes Money
PGHL primarily makes money by manufacturing (and/or sourcing) consumer healthcare products and selling them in India through trade channels such as pharmacies, chemists, modern retail, and distributors, generating revenue from the sale of finished...
Procter & Gamble Health Ltd. Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
92
Very Positive
Cash Flow
84
Very Positive
| Breakdown | TTM | Mar 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 12.84B | 14.08B | 12.18B | 11.51B | 12.30B | 11.14B |
| Gross Profit | 8.88B | 7.97B | 8.69B | 8.09B | 8.46B | 7.61B |
| EBITDA | 4.20B | 4.74B | 3.62B | 3.03B | 3.19B | 2.65B |
| Net Income | 3.07B | 3.27B | 2.51B | 2.01B | 2.29B | 1.93B |
Balance Sheet | ||||||
| Total Assets | 8.94B | 8.41B | 7.94B | 7.94B | 11.01B | 8.94B |
| Cash, Cash Equivalents and Short-Term Investments | 2.86B | 1.85B | 1.89B | 2.44B | 4.53B | 3.19B |
| Total Debt | 95.50M | 92.90M | 76.20M | 95.60M | 120.00M | 28.30M |
| Total Liabilities | 2.75B | 3.17B | 2.57B | 2.56B | 3.50B | 2.77B |
| Stockholders Equity | 6.20B | 5.25B | 5.37B | 5.38B | 7.51B | 6.16B |
Cash Flow | ||||||
| Free Cash Flow | 2.12B | 3.22B | 1.67B | 2.07B | 1.94B | 1.32B |
| Operating Cash Flow | 2.21B | 3.38B | 1.76B | 2.28B | 2.36B | 1.70B |
| Investing Cash Flow | 13.60M | 12.60M | 24.40M | -68.70M | -215.00M | -255.40M |
| Financing Cash Flow | -2.10B | -3.44B | -2.35B | -4.18B | -984.70M | -2.89B |
Procter & Gamble Health Ltd. Technical Analysis
Positive
5751.70
Price Trends
6075.44
Positive
5525.58
Positive
5650.65
Positive
Market Momentum
220.38
Negative
69.13
Neutral
85.20
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PGHL, the sentiment is Positive. The current price of 5751.7 is below the 20-day moving average (MA) of 6480.36, below the 50-day MA of 6075.44, and above the 200-day MA of 5650.65, indicating a bullish trend. The MACD of 220.38 indicates Negative momentum. The RSI at 69.13 is Neutral, neither overbought nor oversold. The STOCH value of 85.20 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:PGHL.
Procter & Gamble Health Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹112.84B | 34.53 | ― | 3.28% | 13.04% | 4.60% | |
68 Neutral | ₹882.66B | 25.41 | ― | 0.33% | 6.08% | 0.77% | |
68 Neutral | ₹1.03T | 53.60 | ― | 0.04% | 16.27% | -6.09% | |
64 Neutral | ₹1.14T | 22.83 | ― | 1.19% | 16.81% | 11.37% | |
60 Neutral | ₹630.97B | 46.32 | ― | 0.24% | 27.48% | 30.05% | |
59 Neutral | ₹15.72B | 26.87 | ― | 0.68% | 11.23% | 13.89% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:PGHL
Procter & Gamble Health Ltd.
6,797.90
952.10
16.29%
IN:AMRUTANJAN
Amrutanjan Health Care Limited
537.90
-148.68
-21.65%
IN:AUROPHARMA
Aurobindo Pharma Ltd
1,534.05
399.86
35.26%
IN:GLENMARK
Glenmark Pharmaceuticals Limited
2,235.90
57.65
2.65%
IN:MANKIND
Mankind Pharma Ltd.
2,491.45
-154.16
-5.83%
IN:ZYDUSLIFE
Zydus Lifesciences Limited
1,142.75
183.99
19.19%
Procter & Gamble Health Ltd. Corporate Events
Procter & Gamble Health Posts Recording and Transcript of Analyst Call
Jun 18, 2026
Procter Gamble Health Limited has announced that the recording and transcript of its virtual analysts and institutional investors call held on June 18, 2026, are now available on the company’s website. The session, attended by senior manage...
Procter & Gamble Health to Host Virtual Investor and Analyst Meet on June 18
Jun 4, 2026
Procter Gamble Health Limited has announced that its management will host a virtual group meeting with analysts and institutional investors on June 18, 2026, at 2:30 p.m. IST, with prior registration required by June 8, 2026. The company emphasiz...
Procter & Gamble Health Books ₹32 Crore Gain From Mumbai Property Sale
Apr 30, 2026
Procter Gamble Health Ltd. has executed a sale deed for certain immovable properties located in Mumbai, in line with disclosure requirements under Indian securities regulations. The transaction will generate an estimated profit of about INR 32 cr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.